Mark Mossler - Feb 14, 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Accounting Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol: CCCC
Transactions as of: Feb 14, 2024
Transactions value $: $0
Form type: 4
Date filed: 4/10/2024, 04:16 PM
Previous filing: Sep 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$0	+18.3K	+1219.33%	$0.00	19.8K	Feb 14, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+27.4K		$0.00	27.4K	Feb 14, 2024	Common Stock	27.4K	$7.31	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025.
F2	Includes 1,500 shares of Common Stock that were inadvertently omitted from the Form 3 filed by the Reporting Person on September 19, 2023.
F3	The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024.